Evidence map›Paper›PMID 41782837›Full record

ArticleiScience2026

Mapping longitudinal lung mycobiome characteristics in severe COVID-19 patients.

Wenxiao Zhang, Chen Peng, Silan Gu, Xiaonan Su, Guojun He, Yijiao Han, Chunfeng He, Liang Zhang, Mingqiang Wang, Lin Zhong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenxiao ZhangDepartment of Critical Care Medicine, Henan Key Laboratory for Critical Care Medicine, Zhengzhou Key Laboratory for Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan 450003, China.
Chen PengMOE Key Laboratory of Biosystems Homeostasis & Protection, and Zhejiang Provincial Key Laboratory of Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310030, China.
Silan GuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Xiaonan SuDepartment of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Guojun HeDepartment of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yijiao HanDepartment of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chunfeng HeDepartment of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Liang ZhangDepartment of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mingqiang WangDepartment of Critical Care Medicine, Henan Key Laboratory for Critical Care Medicine, Zhengzhou Key Laboratory for Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan 450003, China.
Lin ZhongDepartment of Critical Care Medicine, The First Hospital of Pinghu, Pinghu, China.
Lingtong HuangDepartment of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chao JiangMOE Key Laboratory of Biosystems Homeostasis & Protection, and Zhejiang Provincial Key Laboratory of Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the longitudinal dynamics of the lung mycobiome in severe COVID-19 is crucial given the link between viral infection and fungal complications. This prospective, multicenter cohort study tracked respiratory and gut fungal communities in critically ill COVID-19 patients using internal transcribed spacer sequencing and digital droplet PCR. We observed that while the respiratory mycobiome remained stable early after ICU admission, significant alterations occurred during prolonged mechanical ventilation. Although antifungal therapy influenced fungal composition, it did not correlate with survival. Notably, combining lung mycobiome signatures with clinical variables significantly improved mortality prediction, whereas the gut mycobiome showed weak prognostic association. These findings indicate that respiratory fungal dynamics are more closely tied to clinical outcomes than those of the gut in our cohort, suggesting that integrating lung mycobiome profiling could enhance prognostic stratification and management strategies for severe COVID-19.

Indexed as

health sciences

Identifiers

PMID41782837
PMCPMC12955085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.